These findings demonstrate that FRA1 enhances melanoma metastasis at least in part by transcriptionally activating AXL, CDK6, and FSCN1, and targeting CDK4/6 and Fascin could be explored as a therapeutic strategy for FRA1-high metastatic melanoma. The gene discussed is AXL; the disease is metastatic melanoma.